Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.
Related to this article
Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
How Is Targeted Therapy Changing Non–Small Cell Lung Cancer Treatment?
2
Onvansertib Receives FDA Orphan Drug Designation for CMML
3
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
4
Early Survivorship Care Linked to Improved Outcomes in Head and Neck Cancer
5